# A Study to Assess the Efficacy and Safety of PPC-06 (Tepilamide Fumarate)

> **NCT03421197** · PHASE2 · COMPLETED · sponsor: **Dr. Reddy's Laboratories Limited** · enrollment: 426 (actual)

## Conditions studied

- Psoriasis

## Interventions

- **DRUG:** PPC-06 400 mg QD
- **DRUG:** PPC-06 400 mg BID
- **DRUG:** PPC-06 600 mg
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT03421197
- **Lead sponsor:** Dr. Reddy's Laboratories Limited
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2018-01-25
- **Primary completion:** 2020-03-30
- **Final completion:** 2020-03-30
- **Target enrollment:** 426 (ACTUAL)
- **Last updated:** 2022-04-01


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03421197

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03421197, "A Study to Assess the Efficacy and Safety of PPC-06 (Tepilamide Fumarate)". Retrieved via AI Analytics 2026-05-26 from https://api.ai-analytics.org/clinical/NCT03421197. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*